R78C/Matrix-M / University of Oxford - LARVOL DELTA

VAC093: A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine) (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: University of Oxford | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Malaria

VAC087: A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (clinicaltrials.gov) - P2 | N=360 | Not yet recruiting | Sponsor: University of Oxford

New P2 trial • Infectious Disease • Malaria

VAC093: A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine) (clinicaltrials.gov) - P1 | N=56 | Not yet recruiting | Sponsor: University of Oxford

New P1 trial • Infectious Disease • Malaria

A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: University of Oxford | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2024 ➔ Mar 2026 | Trial primary completion date: Jul 2024 ➔ Mar 2026

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Malaria

Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex. (PubMed, Nat Commun) - "We identify that all growth-inhibitory antibody epitopes of RIPR cluster within the C-terminal EGF-like domains and that a fusion of these domains to CyRPA, called "R78C", combined with RH5, improves the level of in vitro parasite growth inhibition compared to RH5 alone. These preclinical data justify the advancement of the RH5.1 + R78C/Matrix-M™ vaccine candidate to Phase 1 clinical trial."

Journal • Infectious Disease • Malaria • EGF

A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: University of Oxford | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Malaria

A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M, Both Alone and in Combination, in Healthy UK Adults (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: University of Oxford

New P1 trial • Infectious Disease • Malaria